These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 6734036)
1. Triamterene kinetics and dynamics in cirrhosis. Villeneuve JP; Rocheleau F; Raymond G Clin Pharmacol Ther; 1984 Jun; 35(6):831-7. PubMed ID: 6734036 [TBL] [Abstract][Full Text] [Related]
2. Kinetics and dynamics of triamterene at steady-state in patients with cirrhosis. Dao MT; Villeneuve JP Clin Invest Med; 1988 Feb; 11(1):6-9. PubMed ID: 3365882 [TBL] [Abstract][Full Text] [Related]
3. Altered hydroxylation rate of triamterene in patients with liver cirrhosis. Gundert-Remy U; Müller-Herrmann R; Mutschler E; Schäfer M; Weber E Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):353-7. PubMed ID: 7118322 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of triamterene and its metabolite in man. Hasegawa J; Lin ET; Williams RL; Sörgel F; Benet LZ J Pharmacokinet Biopharm; 1982 Oct; 10(5):507-23. PubMed ID: 7166735 [TBL] [Abstract][Full Text] [Related]
7. Plasma and urinary levels of triamterene and certain metabolites after oral administration to man. Gundert-Remy U; von Kenne D; Weber E; Geissler HE; Grebian B; Mutschler E Eur J Clin Pharmacol; 1979 Aug; 16(1):39-44. PubMed ID: 499298 [TBL] [Abstract][Full Text] [Related]
8. [Elimination of triamterene, an antikaliuretic, and its phenolic metabolite, 2,4,7-triamino-6-p-hydroxyphenylpteridine, in the urine of subjects with normal liver function and in subjects suffering from liver cirrhosis]. Andrasch H; Fink T; Schmid E Z Gastroenterol; 1971; 9(4):240-5. PubMed ID: 5164739 [No Abstract] [Full Text] [Related]
9. [Pharmacokinetics of triamterene and its active metabolites in renal insufficiency (author's transl)]. Grebian B; Geissler HE; Knauf H; Mutschler E; Schnippenkoetter I; Völger KD; Wais U Arzneimittelforschung; 1978; 28(8):1420-5. PubMed ID: 582410 [TBL] [Abstract][Full Text] [Related]
10. Influence of triamterene and hydroxytriamterene sulfuric acid ester on diuresis and saluresis in rats after oral and intravenous application. Leilich G; Knauf H; Mutschler E; Völger KD Arzneimittelforschung; 1980; 30(6):949-53. PubMed ID: 7191270 [TBL] [Abstract][Full Text] [Related]
11. [Effects of potassium chloride and triamterene on kaliuresis, natriuresis and diuresis in congestive heart failure]. Kabakov AI; Zharov EI Klin Med (Mosk); 1995; 73(5):33-5. PubMed ID: 8815272 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders]. Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD Klin Wochenschr; 1983 Sep; 61(18):883-91. PubMed ID: 6632729 [TBL] [Abstract][Full Text] [Related]
13. Further studies on the natriuretic activity of p-hydroxytriamterene. Ackerman DM; DePalma PD; Shade M Arzneimittelforschung; 1982; 32(9):1023-5. PubMed ID: 6890818 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, natriuretic, antikaliuretic and antimagnesiuretic properties of an acidic triamterene derivative. Netzer T; Ullrich F; Majewski M; Mutschler E Arzneimittelforschung; 1992 Jun; 42(6):807-11. PubMed ID: 1418034 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of the basic triamterene analogue dimethylaminohydroxypropoxytriamterene. Priewer H; Kraft H; Mutschler E Arzneimittelforschung; 1985; 35(11):1688-91. PubMed ID: 4091871 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacological effects of phase-I- and phase-II-metabolites of triamterene (author's transl)]. Knauf H; Mutschler E; Völger KD; Wais U Arzneimittelforschung; 1978; 28(8):1417-20. PubMed ID: 582409 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability. Gilfrich HJ; Kremer G; Möhrke W; Mutschler E; Völger KD Eur J Clin Pharmacol; 1983; 25(2):237-41. PubMed ID: 6628507 [TBL] [Abstract][Full Text] [Related]
18. Reversal of the suppressed potassium excretion during treatment with combinations of antikaliuretic drugs (spironolactone, canrenone, triamterene, amiloride) in patients with liver cirrhosis. Radó JP; Sawinsky I; Juhos E Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):163-7. PubMed ID: 1002353 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of cirrhotic edemas with triamterene, amiloride and spirolactone. New clinical and biological facts]. Vesin P Schweiz Med Wochenschr; 1971 Mar; 101(11):398-401. PubMed ID: 5558553 [No Abstract] [Full Text] [Related]
20. Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function. Williams RL; Thornhill MD; Upton RA; Blume C; Clark TS; Lin E; Benet LZ Clin Pharmacol Ther; 1986 Aug; 40(2):226-32. PubMed ID: 3731685 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]